Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Grows By 48.5%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,990,000 shares, an increase of 48.5% from the March 31st total of 1,340,000 shares. Based on an average daily trading volume, of 987,100 shares, the days-to-cover ratio is currently 2.0 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Brainstorm Cell Therapeutics in a report on Wednesday, March 27th. They issued a “sell” rating for the company.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Stock Performance

NASDAQ BCLI remained flat at $0.53 on Friday. The company’s stock had a trading volume of 266,201 shares, compared to its average volume of 977,687. Brainstorm Cell Therapeutics has a 1-year low of $0.13 and a 1-year high of $3.34. The firm’s 50-day simple moving average is $0.48 and its 200-day simple moving average is $0.33.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings data on Monday, April 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. Sell-side analysts predict that Brainstorm Cell Therapeutics will post -0.28 earnings per share for the current year.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.